Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA)
KNSA moved a median of -0.21% 30 minutes after news, and -0.01% by the close. How KNSA actually reacts to news — the realized, point-in-time move the market made, measured across 427 labeled events over the last three years with zero look-ahead.
KNSA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.10% | 43% | 426 |
| 30-min | -0.21% | 39% | 427 |
| 60-min | -0.14% | 46% | 427 |
| to close | -0.01% | 50% | 422 |
| Middle 50% of KNSA reactions | -1.04% to +0.59% |
|---|---|
| Median reaction (30-min) | -0.21% |
| Measured reactions | 427 |
Half of all Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares news events land between -1.04% and +0.59% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How KNSA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 11 | -0.09% | 46% | +0.69% |
| Coverage initiations | 16 | -0.77% | 31% | +1.93% |
| Rating reiterations | 42 | +0.06% | 52% | -0.65% |
| Price-target raises | 30 | -0.18% | 47% | -0.28% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how KNSA ranks against every other measured name →
That’s how KNSA usually reacts — get an email when it moves on news →Email me when KNSA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KNSA's baseline. Nothing else.
Recent KNSA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference | Press release | GlobeNewswire | -0.75% | +1.10% | |
| Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference | Press release | GlobeNewswire | +1.56% | — | |
| Form 10-Q Kiniksa Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.20% | -0.63% | |
| Form 8-K Kiniksa Pharmaceuticals For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +6.21% | +12.94% | |
| Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | Press release | GlobeNewswire | +6.21% | +12.94% | |
| Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026 | Press release | GlobeNewswire | -0.16% | -0.81% | |
| Form 8-K Kiniksa Pharmaceuticals For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -0.21% | +1.23% | |
| Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.21% | +1.23% | |
| Form 8-K Kiniksa Pharmaceuticals For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.74% | -1.65% | |
| Form 8-K Kiniksa Pharmaceuticals For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | +5.26% | |
| Form 10-Q Kiniksa Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.76% | -1.71% | |
| Form 8-K Kiniksa Pharmaceuticals For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | +5.27% | +15.06% | |
| Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | Press release | GlobeNewswire | +5.27% | +15.06% | |
| Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026 | Press release | GlobeNewswire | -0.88% | -0.49% | |
| Form ARS Kiniksa Pharmaceuticals For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.25% | -1.10% | |
| Form DEF 14A Kiniksa Pharmaceuticals For: May 19 | SEC filing · Form DEF | SEC EDGAR | +0.25% | -1.10% | |
| Form DEFA14A Kiniksa Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | +0.25% | -1.10% | |
| Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis | Press release | GlobeNewswire | -2.29% | -4.47% | |
| Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | -0.33% | +1.78% | |
| Form 10-K Kiniksa Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.94% | -1.70% | |
| Form 8-K Kiniksa Pharmaceuticals For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +5.57% | +1.75% | |
| Form S-8 Kiniksa Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | -0.94% | -1.70% | |
| Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | Press release | GlobeNewswire | +5.57% | +1.75% | |
| Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 | Press release | GlobeNewswire | -0.32% | +0.65% | |
| Form 8-K Kiniksa Pharmaceuticals For: Jan 10 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -4.15% | |
| Form 8-K Kiniksa Pharmaceuticals For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +2.01% | -7.10% | |
| Kiniksa Pharmaceuticals Provides Corporate Update | Press release | GlobeNewswire | -0.94% | -3.45% | |
| Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.68% | -1.21% | |
| Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London | Press release | GlobeNewswire | -0.14% | — | |
| Form 10-Q Kiniksa Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.14% | -4.86% | |
| Form 8-K Kiniksa Pharmaceuticals For: Oct 28 | SEC filing · Form 8-K | SEC EDGAR | -9.88% | -4.48% | |
| Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | Press release | GlobeNewswire | -9.88% | -4.48% | |
| Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025 | Press release | GlobeNewswire | +0.58% | -0.26% | |
| Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis | Press release | GlobeNewswire | -0.06% | -0.67% | |
| Form 8-K Kiniksa Pharmaceuticals For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | +0.94% | +4.35% | |
| Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.13% | -0.21% | |
| Form 10-Q Kiniksa Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.07% | -2.50% | |
| Form 8-K Kiniksa Pharmaceuticals For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +2.21% | — | |
| Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | Press release | GlobeNewswire | +2.21% | — | |
| Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 | Press release | GlobeNewswire | -0.07% | -2.37% | |
| Form 8-K Kiniksa Pharmaceuticals For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +0.31% | +2.64% | |
| Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | Press release | GlobeNewswire | +0.31% | +2.64% | |
| Form 8-K Kiniksa Pharmaceuticals For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.75% | -1.06% | |
| Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.02% | +0.81% | |
| Form DEFA14A Kiniksa Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | -2.20% | -2.58% | |
| Form DEFA14A Kiniksa Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | +1.77% | +3.23% | |
| Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis | Press release | GlobeNewswire | -0.08% | +3.65% | |
| Form 10-Q Kiniksa Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.08% | +3.65% | |
| Form 8-K Kiniksa Pharmaceuticals For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | +10.93% | +16.42% | |
| Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution | Press release | GlobeNewswire | +10.93% | +16.42% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KNSA section they belong to.
Where else KNSA is measured.
KNSA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| LeMaitre Vascular, Inc. (LMAT) | 430 | +0.05% | 54% |
| TRULIEVE CANNABIS CORP (TCNNF) | 429 | +0.41% | 58% |
| Veracyte, Inc. (VCYT) | 427 | -0.15% | 46% |
| Moleculin Biotech, Inc. (MBRX) | 426 | -0.21% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares's median reaction calculated?
Every labeled KNSA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 427 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of KNSA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KNSA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.